Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report

Anticancer Res. 2021 Jul;41(7):3635-3638. doi: 10.21873/anticanres.15152.


Background: Treatment of refractory/relapsing diffuse large B cell (R/R DLBCL) lymphoma remains a challenge. Radiation therapy (RT) has versatile roles in R/R DLBCL treatment: it can be used in the peri-transplant setting for transplant-eligible candidates, or as a salvage or palliation therapy depending on the extent of the disease in transplant-ineligible patients. The introduction of chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of R/R DLBCL. RT has been used as a bridging therapy to CAR T-cell therapy in order to control disease progression during its manufacturing period. However, optimal RT and CAR T-cell therapy integration is still unknown. Salvage strategies for R/R DLBCL post-CAR T-cell therapy have been little studied.

Case report: Here, we present a case of primary refractory DLBCL with residual disease post-CAR T-cell therapy successfully treated with salvage RT.

Conclusion: Radiotherapy could be an effective salvage strategy for R/R DLBCL post-CAR T-cell therapy. Exact mechanisms await exploring.

Keywords: CAR T-cell therapy; R/R DLBCL; post-CAR T salvage therapy; radiation therapy.

Publication types

  • Case Reports

MeSH terms

  • Cell- and Tissue-Based Therapy / methods
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / metabolism*
  • Lymphoma, Large B-Cell, Diffuse / radiotherapy*
  • Middle Aged
  • Neoplasm Recurrence, Local / metabolism
  • Neoplasm Recurrence, Local / radiotherapy*
  • Neoplasm, Residual / metabolism
  • Neoplasm, Residual / radiotherapy
  • Receptors, Chimeric Antigen / metabolism*
  • Salvage Therapy / methods
  • T-Lymphocytes / metabolism
  • T-Lymphocytes / radiation effects


  • Receptors, Chimeric Antigen